Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
23.32
-0.10 (-0.43%)
At close: Apr 28, 2026, 4:00 PM EDT
23.29
-0.03 (-0.13%)
After-hours: Apr 28, 2026, 4:02 PM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
$1,062,350
Profits / Employee
-$45,596
Market Cap
2.92B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Arcus Biosciences | 601 |
| Beam Therapeutics | 511 |
| Denali Therapeutics | 503 |
| Dyne Therapeutics | 258 |
| Alumis | 224 |
| Relay Therapeutics | 192 |
| Soleno Therapeutics | 182 |
| Kodiak Sciences | 124 |
ARQT News
- 1 day ago - Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - GlobeNewsWire
- 6 days ago - Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - GlobeNewsWire
- 13 days ago - Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - GlobeNewsWire
- 14 days ago - Arcutis Biotherapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 4 weeks ago - Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 5 weeks ago - Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - GlobeNewsWire
- 7 weeks ago - Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology - GlobeNewsWire